AIMI Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -23156.25% compared to AIM ImmunoTech's net margin of --. AIM ImmunoTech's return on equity of -877.96% beat Perspective Therapeutics's return on equity of --.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2009.71%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.2692 which suggests that it could grow by 350.13%. Given that AIM ImmunoTech has higher upside potential than Perspective Therapeutics, analysts believe AIM ImmunoTech is more attractive than Perspective Therapeutics.

AIM ImmunoTech has a beta of 0.944, which suggesting that the stock is 5.648% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $16K, which are larger than Perspective Therapeutics quarterly revenues of --. AIM ImmunoTech's net income of -$3.7M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 2,981.06x versus 22.34x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -23156.25% compared to AIM ImmunoTech's net margin of 12.06%. AIM ImmunoTech's return on equity of -877.96% beat Electromed's return on equity of 16.57%.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2009.71%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 89.34%. Given that AIM ImmunoTech has higher upside potential than Electromed, analysts believe AIM ImmunoTech is more attractive than Electromed.

AIM ImmunoTech has a beta of 0.944, which suggesting that the stock is 5.648% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $16K, which are smaller than Electromed quarterly revenues of $15.7M. AIM ImmunoTech's net income of -$3.7M is lower than Electromed's net income of $1.9M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Electromed's PE ratio is 25.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 2,981.06x versus 2.93x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -23156.25% compared to AIM ImmunoTech's net margin of -35.79%. AIM ImmunoTech's return on equity of -877.96% beat Protalix BioTherapeutics's return on equity of 10.9%.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2009.71%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 839.6%. Given that AIM ImmunoTech has higher upside potential than Protalix BioTherapeutics, analysts believe AIM ImmunoTech is more attractive than Protalix BioTherapeutics.

AIM ImmunoTech has a beta of 0.944, which suggesting that the stock is 5.648% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.210, suggesting its less volatile than the S&P 500 by 120.951%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $16K, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. AIM ImmunoTech's net income of -$3.7M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 2,981.06x versus 2.09x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -23156.25% compared to AIM ImmunoTech's net margin of 0.18%. AIM ImmunoTech's return on equity of -877.96% beat Xtant Medical Holdings's return on equity of -26.62%.

AIM ImmunoTech has a consensus price target of $1.50, signalling upside risk potential of 2009.71%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 181.13%. Given that AIM ImmunoTech has higher upside potential than Xtant Medical Holdings, analysts believe AIM ImmunoTech is more attractive than Xtant Medical Holdings.

AIM ImmunoTech has a beta of 0.944, which suggesting that the stock is 5.648% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $16K, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. AIM ImmunoTech's net income of -$3.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 2,981.06x versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.